Safety and Pharmacokinetics of CKD-333 vs Co-administration of CKD-330 and D085 in Healthy Volunteers

Phase 1, randomised, open-label trial of candesartan cilexetil, amlodipine and atorvastatin in hypertension (HTN) and dyslipidemia (3 arms), sponsored by Chong Kun Dang Holdings. Primary endpoints: Area Under the Concentration-time curve to the last measurable concentration at 72 hours and Maximum Plasma Concentration at 72 hours. Status: unknown.